Success Metrics

Clinical Success Rate

88.9%

Based on 32 completed trials

Completion Rate

89%(32/36)

Active Trials

4(7%)

Results Posted

38%(12 trials)

Terminated

4(7%)

Phase Distribution

Ph phase_4

28%

Ph phase_3

25%

Ph early_phase_1

Ph phase_1

Ph not_applicable

Ph phase_2

19%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution52 total trials

Early Phase 1First-in-human

3(5.8%)

Phase 1Safety & dosage

4(7.7%)

Phase 2Efficacy & side effects

11(21.2%)

Phase 3Large-scale testing

14(26.9%)

Phase 4Post-market surveillance

16(30.8%)

N/ANon-phased studies

4(7.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

84.2%

32 of 38 finished

Non-Completion Rate

15.8%

6 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(4)

Completed(32)

Terminated(6)

Other(15)

Detailed Status

Completed32

unknown15

Terminated4

Recruiting3

Withdrawn2

Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

88.9%

Most Advanced

Phase 4

Trials by Phase

Early Phase 13 (5.8%)

Phase 14 (7.7%)

Phase 211 (21.2%)

Phase 314 (26.9%)

Phase 416 (30.8%)

N/A4 (7.7%)

Trials by Status

completed3256%

terminated47%

unknown1526%

active_not_recruiting12%

recruiting35%

withdrawn24%

Recent Activity

4 active trials

Showing 5 of 57

completedphase_1

Drug-Drug Interaction Study to Evaluate the Effect of Colestilan on the Pharmacokinetics of Single Doses of Candesartan Cilexetil in Healthy Subjects

NCT01976572

recruiting

Clinical Trials (57)

Showing 20 of 57 trialsScroll for more

NCT01976572Phase 1

Drug-Drug Interaction Study to Evaluate the Effect of Colestilan on the Pharmacokinetics of Single Doses of Candesartan Cilexetil in Healthy Subjects

Completed

NCT03460327

Bariatric Surgery and Pharmacokinetics of Candesartan

Recruiting

NCT03583866Early Phase 1

Adiposity and Endothelin Receptor Function

Active Not Recruiting

NCT05328635

Post-traumatic Headache Multidisciplinary Study

Completed

NCT03640312Phase 2

Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension

Completed

NCT05321875Phase 3

Early Treatment With Candesartan vs Placebo in Genetic Carriers of Dilated Cardiomyopathy (EARLY-GENE Trial)

Recruiting

NCT04606563Phase 3

Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?

Terminated

NCT04138316

CandeSpartan Study. Candesartan Spanish Response-prediction and Tolerability Study

Completed

NCT02646982Phase 2

Candesartan's Effects on Alzheimer's Disease And Related Biomarkers

Completed

NCT04430959Early Phase 1

Candesartan as an Adjunctive Treatment for Bipolar Depression

Withdrawn

NCT01062451Phase 1

An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence

Completed

NCT01678794Phase 1

CR Aim #2 - AT1 Receptor Blockade & ACE Inhibition Effect on Humoral Function

Completed

NCT03688633Phase 2

Candesartan in Peripheral Neuropathy

Terminated

NCT04351724Phase 2

Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)

Unknown

NCT01984164Phase 2

CAndesartan vs LIsinopril Effects on the BRain

Completed

NCT04429633Not Applicable

Strain vs. Left Ventricular Ejection Fraction-based Cardiotoxicity Prevention in Breast Cancer

Unknown

NCT03770936Phase 3

Effect of Some Drugs on Liver Fibrosis

Recruiting

NCT01794455Phase 4

Effects of Cerebral Hypoperfusion and Its Reversal on Late-Life Depression

Terminated

NCT02879721Early Phase 1

Expression and Function of the Renin-Angiotensin System in the Esophagus

Completed

NCT01827202Phase 4

RAS Quantification in Patients With Aliskiren or Candesartan

Completed

Drug Details

Intervention Type: DRUG
Total Trials: 57